Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Sep 1;8(43):75742-75755.
doi: 10.18632/oncotarget.20608. eCollection 2017 Sep 26.

Cell-free circulating tumor DNA analysis for breast cancer and its clinical utilization as a biomarker

Ru Wang  1 , Xiao Li  1 , Huimin Zhang  1 , Ke Wang  1 , Jianjun He  1
Affiliations
Review

Cell-free circulating tumor DNA analysis for breast cancer and its clinical utilization as a biomarker

Ru Wang et al. Oncotarget. .

Abstract

Circulating tumor DNA (ctDNA) in the blood of cancer patients contains much information on genetic and epigenetic profiles associated with cancer development, progression, and response to therapy. Analysis of ctDNA provides an opportunity for non-invasive sampling of tumor DNA repetitiously and therefore advance precision medicine. Recent development in massively parallel sequencing and digital genomic techniques support the analytical and clinical validity of ctDNA as a promising 'liquid biopsy' in human cancer. In this review, we discussed the current status of cell-free ctDNA including ctDNA biology, recently developed techniques for ctDNA detection, breast cancer specific detecting strategies, with a focus on clinical applications of ctDNA-based biomarkers in breast oncology.

Keywords: biomarker; breast cancer; ctDNA; liquid biopsy.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Tumor cells release small fragments of cell-free DNA into circulation by multiple mechanisms, including necroptosis, apoptosis, secretion from tumor cells, and so on
Several strategies can be used for the analysis of circulating tumor DNA, such as quantification of cfDNA, detection of cell-free DNA integrity, microsatellite alterations, gene mutations, methylation patterns, and nucleosome. Some potential clinical applications of ctDNA as liquid biopsy to breast cancer management include screening for cancer (potentially as a supplement to mammography), monitoring disease burden, predicting recurrence, determining prognosis, assessing therapy response, tracking clone evolution, and deciphering tumor heterogeneity.
See this image and copyright information in PMC

References

    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65:5–29. - PubMed
    1. DeSantis CE, Fedewa SA, Goding Sauer A, Kramer JL, Smith RA, Jemal A. Breast cancer statistics, 2015: Convergence of incidence rates between black and white women. CA: A Cancer Journal for Clinicians. 2016;66:31–42. - PubMed
    1. Massihnia D, Perez A, Bazan V, Bronte G, Castiglia M, Fanale D, Barraco N, Cangemi A, Di Piazza F, Calo V, Rizzo S, Cicero G, Pantuso G, et al. A headlight on liquid biopsies: a challenging tool for breast cancer management. Tumour Biol. 2016;37:4263–4273. - PubMed
    1. Schwarzenbach H, Hoon DS, Pantel K. Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer. 2011;11:426–437. - PubMed
    1. Mandel P, Métais P. [Les acides nucléiques du plasma sanguin chez l’homme.][Article in undetermined language] C R Seances Soc Biol Fil. 1948;142:241–243. - PubMed